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Abstract
The miscarriages’ investigation should include a familiar history, gynecological 
examination and a full laboratory testing including hormonal control, as well as 
karyotype, maternal immune control and thrombophilia testing. If the physician 
suspects the cause of abortions is chromosomal due to heredity, a special blood test 
(karyotype) for the pair is recommended. Chromosomal abnormalities are the most 
common reason for first trimester abortions, and are impossible to be prevented. 
Based on the above data, abortion and the subsequent possible infertility should 
not be considered as a personal failure for the woman and the treating physician. 
Nowadays, medical advancement provides many options combined with psycho-
logical support can actually reduce the miscarriages’ risk.
Keywords: spontaneous abortions, recurrent abortions, diagnosis, therapy
1. Introduction
Spontaneous abortions are considered as one of the most common complications 
in pregnancy. Abortion is defined as the ejection of the fetus until the 20th week 
and is clinically classified based on ultrasound evaluation. Threatened abortion 
is usually accompanied by vaginal bleeding without affecting the pregnancy. 
Incomplete miscarriage is described as incomplete passage of conception products. 
Complete, when all pregnancy products are spontaneously aborted. Septic abortion 
when endometrial infection coexists. Finally, recurrent abortions that are defined 
when three consecutive abortions occur before 20th weeks of gestation [1–5].
Induced Abortion and Spontaneous Early Pregnancy Loss - Focus on Management
2
More than 80% of miscarriages occur up to 12 weeks. The percentage of clini-
cally recognized abortions (appeared after 6th week) is estimated to be 12–15%. 
More analytically, 2 miscarriages occurred in 5% of women and ≥3 miscarriages 
in 1–3% of women [1–5]. Recurrent miscarriages consist of a serious problem for 
women with physical and psychological consequences. Abortions and especially 
recurrent miscarriages are considered as heterogeneous groups in regard to etiology 
[1–5]. Two or more causes can coexist, whereas about 50% of cases are character-
ized as idiopathic as a result of genetic, anatomical, endocrine, genetic, anatomical, 
endocrine, autoimmune factors or infections exclusion [1–5].
The number of clinically recognized miscarriages to total number of pregnan-
cies is about 10–15%, while the equivalent of early abortions based only on human 
chorionic gonadotropin (hCG) measurements is actually much higher (50–60%) 
and interestingly before and after the implantation it is 30% but are not perceived 
[1, 6–10].
A positive correlation has been identified between the mother’s biological age 
and the incidence rate of spontaneous abortions. So, a progressive increase of 
10-fold afterwards the age of 40 is observed compared to younger women aged 
<35 years [1, 6–10].
Regarding the gestational age in first trimester and the abortion risk, this counts 
to 4 and 2%, respectively, in 6th and 8th week of gestation [1, 6–10]. The risk of 
recurrence in the next pregnancy is minor except of cases diagnosed with congeni-
tal uterine abnormalities [1, 6–10].
1.1 Recurrent miscarriages
Recurrent miscarriages are defined as three or more consecutive embryos losses 
weighing under 500 g. According to bibliography we can find different definitions 
for miscarriages [1, 11, 12]: two or more miscarriages of clinical pregnancies [7]; 
three or more miscarriages of the first trimester or one or more miscarriages of 
the second trimester; three or more miscarriages <14 weeks [1, 11, 12]. Frequency 
appearance is of quite large (1 in every 300 pregnancies).
Recurrent miscarriages (frequency 1–3% among couples of reproductive age) 
usually occur during the first trimester and relative risk increases with the number 
of previous miscarriages [1, 11, 12]. Consequently, after the first miscarriage, this 
risk reaches 24%, after the second one to 26% and after the third it amounts to 32% 
[1, 11, 12]. About 10–15% of all clinical recognized pregnancies are aborted and the 
theoretical risk for three consecutive pregnancy losses is 0.34% [1, 11, 12].
Receiving history includes:
• the gestational age of spontaneous abortions
• the certification in the presence of embryonic pole and heart function
• the symptoms related to the antiphospholipid syndrome and family history of 
automatic abortions
The possibility to predict the risk of recurrence depends on several factors like as 
maternal age, fetal parental karyotypes gestational age, presence of various mater-
nal laboratory findings [1, 11, 12].
About 80% of abortions occur during the first trimester, 50–60% of them are 
based on genetic abnormalities. The risk of pregnancy loss is 2–5% after the recog-
nition of heart function, 5% for women who report two miscarriages and finally 1% 
of women mentioning more than three miscarriages [1, 11, 12].
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Investigation of recurrent pregnancy loss (RPL) begins with personal history, 
followed by laboratory, genetic, hormonal, anatomic, immunologic, thrombophilic 
factors and infective reasons that can affect pregnancy outcome. It is quite often 
that 2 or more factors coexist [11–20]. In half of cases, etiology cannot be identified, 
so it is described as “Recurrent miscarriages of unknown etiology” [1, 11, 16].
2. Clinical examination
During the clinical examination, a gynecological examination and a check for 
hyperandrogenemia and hyperprolactinemia signs should be done [1, 17].
3. Laboratory check
A laboratory control includes:
• Karyotype in couple
• Hysteroscopy or hysterosalpingography (HSG)
• Anticardiolipins and LA
• Control of progesterone levels in the middle of the luteal phase cycle
• Check the levels of FSH,LH,PRL and testosterone (2–5th day of period)
• TVS (transvaginal ultrasound) [1, 13–20].
It is of great importance in thrombophilia examinations control to include V 
Leiden factor and prothrombin 20210 mutation [1, 15–20].
4. Anatomical factors
Anatomical abnormalities that can cause miscarriages are typically recognized 
using hydrosonohysterography (HSG), hysteroscopy, laparoscopy, possible in same 
cases magnetic resonance and recently three-dimensional ultrasonography.
Congenital anomalies malformations of the female reproductive tract uterine 
anatomical abnormalities, such as bicornuate uterus or uterine diaphragm, polyps, 
heart-shaped ultrasound fibroids are results from failure completion of bilateral 
duct elongation, fusion, septal resorption of müllerian ducts [13–15].
Especially with regard to fibroids, they may block the development of early 
pregnancy, but their influence on spontaneous abortions is also affected by other 
factors such as age and hormonal disorders. Müllerian anomalies occurred in 8–10% 
of women, who had three or more consecutive spontaneous abortions. The fibro-
muscular tissue in septate uterus is poorly vascularized fibromuscular tissue that is 
associated with the highest pregnancy loss rate in some studies reporting an average 
of 65%. Except the above-mentioned abnormality, high frequency for pregnancy 
loss is noticed in didelphys, bicornuate and unicornuate uterus [13–15].
Intrauterine adhesions (Asherman syndrome) are acquired uterine defect result-
ing from infection, endometritis and unsuccessful curettage, which is associated 
with recurrent miscarriage, oligomenorrhea and amenorrhea and bad prognosis. 
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Recommended treatment in these cases includes balloon catheter, administration of 
estrogen and progestin medication [1, 16–18].
Uterine cavity abnormalities including submucosal, intramural >40 myomas, 
polyps are associated to poorly vascularization of endometrium led to failure 
of implantation, placenta tissue development and contribute to pregnancy loss. 
Cervical insufficiency is described as an acquired uterine anomaly, which is 
depending in painless cervical dilatation, effacement and inability of the uterine 
cervix to retain the amniosac is the commonest reason for abortion in the second 
trimester [16–18]. Exposure of the embryo in diethylstilbestrol DES and a variety 
of environmental factors like thalidomide, infectious agents and ionizing radia-
tion affects the uterine morphology by triggering changes in both the location and 
amount of HOXA/Hoxa expression in the development of Müllerian ducts. No 
prospective studies exist. The HOXA genes along the Müllerian ducts, influencing 
the development of Müllerian ducts are: HOXA9 Oviduct, HOXA10, HOXA11 
Uterus, HOXA11, HOXA13 Cervix and HOXA13 Upper vagina [1, 19–21].
5. Chromosomal abnormalities
Genetics reasons of recurrent pregnancy loss be subdivided in embryo abnor-
malities resulting of known parental genetic pathology and embryo aneuploidy in 
parents to be chromosomally normal A variety of genetic factors including aneu-
ploidy (gain or loss of a chromosomal), chromosomal imbalance resulting from 
harbored translocations, inversions, deletions, duplications within chromosomes, 
single gene mutations led to recurrent pregnancy loss (RPL) [1, 22–33]. In 3–5% 
of couples with RPL, the ratio of parental chromosome abnormalities in contrast 
to the general population is 0.7%. The most common chromosomal abnormalities 
leading to RPL are balanced translocations. The first chromosomally abnormal 
abortion was reported in 1961. Chromosomal abnormality is approximately 
responsible for half of the clinically diagnosed abortions in the first trimester. 
About 50% of them are autosomal trisomy, 20% monosomy XO, 20% polyploidy 
and 10% variety of other  abnormalities [33–35].
5.1 Karyotype examinations in aborted fetus
• Karyotype in couple
• No need for molecular karyotype
• No need for microdeletions control
About 25% of cases exist in the first trimester, in which although the embryos 
are normal and euploid, they cannot develop properly. The reasons include 
women with müllerian agenesis and other significant anatomic abnormalities. In 
the second trimester, the abortion incidence due to a chromosomal abnormality 
is <20%. Structural chromosome abnormalities (Robertson-type balancing and 
translocations).
X-inactivation chromosome (?)
aneuploidy of spermatozoa (?).
Recurrent abortion (RA) as well as repeated IVF failure (RIF) has a common 
underlying factor which is the significant increase in the rate of chromosomal 
abnormality [35]. The results also suggest that in women with recurrent abortions, 
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the transfer of normal embryos improves the pregnancy rate and live-birth rate in 
both younger and older women. In these cases, preimplantation genetic diagnosis is 
recommended, testing for structural chromosomal aberrations like translocations, 
inversions, removing cells from the resultant embryo or oocyte evaluating the cells 
for genetic abnormalities and determine the optimal embryos for uterine transfer 
[35–37]. Last year, novel technologies like microarrays, fluorescence in situ hybrid-
ization and biopsy of embryo blastocyst are widely used [34–36].
5.2 Lifestyle and environment
Women with RPL have reproductive difficulties because they are concerned 
about various toxins and agents within the environment. It is of great importance 
to counseling these couples in health care institutions to have current and accurate 
information and to avoid exposures to these substances [37, 38]. The rate of sponta-
neous abortion is positively associated to cigarette smoking, alcohol consumption, 
obesity, body mass index (BMI, weight in kilograms divided by square of height in 
meters) >30 kg/m2, caffeine intake (excess of 300 mg/day) and ionizing radiation 
[37, 38].
6. Immunological factors
In some case, a failure to activate a normal control mechanism to prevent an 
immune reaction against self is observed and this subsequently led to autoim-
mune response. Natural killer cells are attached to the cytotrophoblast of the 
embryo. However, the mechanism by which such cells may or may not affect 
the embryo is not proven. When implantation occurs, there is a slight inflam-
matory response. Patient with infertility and recurrent miscarriages develop 
less prominent reaction that may prevent the embryo from implanting [39, 40]. 
Autoimmune abortions are thought to be caused by the presence of autoantibod-
ies that already exist in the woman against membrane phospholipids, thyroid 
antigens, nuclear antigens, syncytiotrophoblast cells or against other organelles 
or tissues [39, 40].
About 10–15% of all women have antinuclear antibodies regardless of medical 
history of RPL. In cases of presence of antinuclear antibodies, the possibility of 
successful pregnancy outcome is independent of antibodies existence [39, 40].
Autoimmune factors causing RPL are: antiphospholipid antibody syndrome, 
aPL antibodies (anticardiolipin antibodies and lupus anticoagulant), ß2 glycopro-
tein antibodies, phosphatidyl serine. Antibody hemeostasis in systemic circula-
tion is different between men and women, just because women need to be better 
equipped, so that they can cope with the required immune tolerance in fetal anti-
gens derived from them [39, 40].
The “thermostat” is therefore positioned higher in women, as a result, autoim-
mune diseases have much higher incidence in women. If autoantibodies are found in 
relation to a pathological condition, this means: whether they are the pathogenetic 
factors of the disease (autoimmune hemolytic anemia); whether it is the result of 
a previous pathological process (autoantibodies against cardiac muscle after its 
destruction) and whether they are causative agents without damaging themselves, 
which is the most common, as is believed [40, 41].
If the antibodies are present in the mother’s serum as a result of allogeneic 
stimulation during pregnancy, then they are not considered to be autoantibod-
ies unless they exist previously [40, 41]. Until now, there is no common point of 
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the effect of pregnancy on the production of autoantibodies. Although no clear 
increase in autoantibodies has been found during normal pregnancy, an increase in 
some of them has been reported in pathological pregnancies, most of which have 
been described as antiphospholipid antibodies [40, 41]. In the group of recurrent 
miscarriages, 15% were certified positive findings for the lupus anticoagulant or 
antiphospholipid antibodies or both of them. It is important to notice that lupus 
anticoagulant is not synonymous with systemic lupus erythematosus (SLE), where 
it is found in only 5–15% [40, 41].
6.1 Antiphospholipid antibodies
Antiphospholipid antibodies (APAs) are a family of immunoglobulins which 
react with anions of phospholipids or anions of phospholipid-protein complexes in 
the cell membrane of the syncytiotrophoblast [1, 41, 42].
The finding of aPL antibodies is associated to adverse pregnancy outcomes such 
inducing vessel thrombosis of the surrounding placental maternal unit, placenta 
infarction, and fetal death. The primary mechanism in the first trimester depends 
on a deleterious effect directly on trophoblastic cells, inhibition of secretion of 
human placental chorionic gonadotropin, and the expression of trophoblast cell 
adhesion molecules (a1, a5 integrins, E, VE-cadherins). The most widely used are 
anti-cardiolipin (diphosphatidyl-glycerol) [1, 41, 42].
Others are anti-phosphatidylserine anti-phosphatidylethanolamine, anti-
phosphatidylcholine, anti-phosphatidylinositol, and phosphatidic acid. Large 
variation in APHA measurements between laboratories and in the same labora-
tory for the same patient and great fluctuation in the values during pregnancy 
are observed.
It is questionable whether the same or other substnces (anti-β2-glycoprotein I) 
have similar impact according to recurrent pregnancy loss [42–45].
Possible action of APAs on miscarriages:
Abnormalities in endothelial cell function of vessels (decrease in production 
of arachidonic acid prostacyclin and a relative increase of thromboxane which is a 
potent vasoconstrictor and promotes platelet aggregation).
Obstructive angiopathy (reaction with anion phospholipids exposed after vessel 
damage).
Platelet stimulation and/or adhesion (in damaged platelets, APAs bind phos-
phatidylserine to the structural element of the inner membrane of the platelets and 
promote platelet aggregation and thrombus formation).
Placental infarction (microscopic arterial thrombosis and necrotic fibrous 
deposition have been found). It also appears to be due to reduced flow in the vessels, 
as has been found to occur in the umbilical and maternal arteries in patients with 
lupus or APS. This situation resembles a destruction of the vessels through antibod-
ies after heart transplantation, coronary bypass, or angioplasty [42–45].
Inhibition of protein C stimulation in S. These two proteins, after their activa-
tion, inactivate clotting factors Va and VIIa. Stimulating their stimulation creates an 
increased tendency for coagulation.
Reduction of levels of annexin V, a protein with potent antithrombotic effect on 
the surface between trophoblast and endothelial cells.
Effect on placental function: (ACA inhibits the secretion of gonadotropin secre-
tion from placenta, which can act on the secretion of hormones from the placenta, 
negatively affecting the viability of the fetus).
Phospholipids bind to the surface of trophoblast, and this results in direct 
destruction of cells, inhibition of syncytia formation, decrease of hCG production 
and defective penetration into maternal peristalsis.
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6.2 Autoimmune factors
Antiphospholipid syndrome: high levels of antiphospholipid antibodies and his-
tory of miscarriages and/or endometrial death and/or thrombosis—risk of autoim-
mune in subsequent pregnancy ~90% [46, 47].
6.3 Clinical criteria
Vascular thrombosis (one or more clinical episodes of venous, arterial, or small 
vessel thrombosis in any tissue or organ).
Gestational complications (one or more recurrent miscarriages after the 10th 
week of gestation, one or more preterm births and one or more recurrent miscar-
riages before the 10th week of gestation).
Laboratory criteria: cardiolipin antibodies (IgG or IgM anti-cardiolipins, at 
moderate or high levels in two or more measurements over a period of at least 
6 weeks between them).
Lupus anticoagulant (in two or more measurements at least 6 weeks apart) 
[44–47].
7. Antiphospholipid syndrome: management
Steroids (complications: pregnancy and prematurity) are not recommend based 
on current publication evidence. It is reported that the maternal and fetal complica-
tions increase without affecting the pregnancy outcome and live births [43–47].
7.1 Prednisolone, between 10 and 20 mg daily dosage
It may prevent recycling in the circulation of cardiolipins or suspend the discharge 
of embryo toxic factors or factors associated with HLA. In addition, it lowers NK 
(CD56+/CD16+) cell percentage. It has been associated with pregnancy hyperten-
sion, diabetes mellitus, and mainly with premature labor and low-weight new-born 
babies. Aspirin should be given preconceptually. Aspirin in low dosage (80–100 mg 
daily) may suspend cyclooxygenase (COX) action on platelets, by suspending the 
composition of thromboxane thrombosis and thus preventing vascular thrombosis in 
placental blood vessels. At discontinuance after around 32 weeks, heparin (does not 
pass the placenta) should be started after the first positive pregnancy test and should 
be continued until of labor to avoid thrombosis risk: hypo-heparin, for example, 
heparin of low molecular weight, one injection daily. Anticoagulant action (rein-
forces the action of antithrombin III), while it may bind AFAs, thus prevents chori-
onic villus sampling (CVS) phospholipids from being destroyed, by assisting in the 
successful implantation in the early stages of pregnancy [43–47]. Thrombocytopenia 
and osteoporosis check-up. Discontinuation after 34 weeks of pregnancy and prior to 
giving birth. (Now in labor).
It appears that combining aspirin and heparin has the best results. Patients should 
start taking heparin as early as possible when pregnant and continue until labor 
and during puerperium [42–50]. Combination of aspirin and heparin is associated 
with better results. Heparin subcutaneously, for example, low molecular weight 
heparin one injection per day may prevent recycling of circulating anti-cardiolipins 
or suppress the secretion of embryotoxic agents or HLA-related agents. It also 
reduces the percentage of NK (CD56+/CD16+) cells [46–50]. It has been associated 
with gestational hypertension and diabetes mellitus and mainly with premature 
labor and low birth weight neonates. Combination of aspirin with heparin, aspirin 
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with prednisolone, or all three is associated to satisfactory results. It seems that the 
combination of aspirin and heparin works best. Heparin should be started as soon 
as possible in pregnancy and should be maintained until the labor and postpartum 
especially when the risk of thrombosis is high [42–50]. Intravenous immunoglobulin 
therapy IVIG (no superior to the combination of aspirin and heparin) Intravenous 
injection of high doses of gamma globulin (300–500 mg/kg body weight). An increase 
inT-immunosuppressive cells, decreases the activity of natural killer cells, inhibition 
of transport by the mother’s placenta of IgG, inhibition of Fc receptors in macro-
phages and, especially, multivalent immunosuppression. To avoid the adverse reac-
tions of heparin therapy, it is recommended to add calcium 600 mg twice daily and 
vitamin D supplementation 400 IU daily to decrease the osteoporosis risk. The platelet 
count should be weekly examined in the first two weeks after treatment with heparin 
because bleeding could occur due to heparin induced thrombocytopenia [42–50].
8. Endocrine factors
Mentioned here are polycystic ovary syndrome (PCOS) due to high levels of 
luteinizing hormone (LH), corpus luteum (CL) deficiency, nonregulated diabetes 
mellitus during conception period, thyroid malfunction, thrombophilic factors, 
alloimmunological factors: PCOS, menstrual complications, hypertrichosis, poly-
cystic ovaries, and resistance to insulin. The contribution of endocrinological factor 
as reasons of RPL including luteal phase deficiency, untreated hypothyroidism, 
abnormal glucose metabolism hyperprolactinemia, and diminished ovarian reserve 
is average by 8–12% [51–54].
8.1 Corpus luteum deficiency
Corpus luteum malfunction association with RPLs still remains a hypothesis, 
despite the fact that there are studies that reveal that it is responsible for 12–28% 
of cases. Luteal phase deficiency is defined as an inability of the corpus luteum 
to secrete progesterone either in increased satisfactory amounts or for too short 
duration. This inability to function is established by alteration of preovulatory 
estrogen stimulation, which led to poor oocyte quality and a poorly functioning 
corpus luteum. The diagnosis should be confirmed either with endometrial biopsy 
which is not recommended as diagnostic modality or if serum progesterone levels 
are <10 ng/ml [51–54]. Strategy of treatments of corpus luteum malfunction has 
a wide variation and includes administration of progesterone or human chorionic 
gonadotropin induction or a combination of these. Progesterone administration 
either as intravaginal suppositories 50–100 mg or as intramuscular injections 50 mg 
IM is considered necessary only within RCTs [51–54].
8.2 Hyperprolactinemia
Hyperprolactinemia is an endocrinopathy which led to infertility and abortions 
due to anovulation. It is not clear whether it is associated with RPLs. Increased 
prolactin levels interact with the hypothalamic pituitary ovarian axis, reducing the 
folliculogenesis or leading to a small duration of luteal phase. Studies reveal that it 
affects progesterone discharge at luteal stage; however, this situation has not been 
confirmed in humans. A randomized control trial including 64 hyperprolactinemic 
women with RPL treated with bromocriptine was associated with a higher rate of 
successful pregnancy, whereas PRL levels were significantly higher in women that 
miscarried (85.7 vs. 52.4%) [55–58].
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8.3 Dopamine agonists
Currently, there is no sufficient evidence for effectiveness of dopamine agonist 
evaluation in preventing future miscarriage in women with idiopathic hyperprolac-
tinemia and a history of recurrent miscarriage [55–57].
8.4 Diabetes mellitus
Women with nonregulated DM I: diabetes mellitus (DM) in women with RPLs 
is associated with a higher incidence of spontaneous abortions in relation to women 
with euglycemic metabolism preconceptually. A well controlled diabetes mellitus 
decreases the rates of recurrent pregnancy loss. Testing for fasting insulin and 
glucose and hemoglobin A1c usually have an increased modality for the evaluation 
of insulin resistance. The metformin administration seems to improve pregnancy 
outcome and is it safe in the first trimester [55–57].
8.5 Thyroid gland disorders
It is well known that hypothyroidism without therapy increases the risk of 
abortion. Treatment before attempting a pregnancy is clearly recommend as well 
as keeping a TSH level between 1.0–2.5 UIU/ml in the first trimester. In cases with 
TSH levels higher than 2.5 MIU/ml, levothyroxine should be started at a minimum 
dose of 50 μg/d.
Anti-thyroid Abs is associated with RPLs when detected before the start of 
pregnancy or at an early stage.
Hypothyroidism is involved with obstetric complications like infertility, abor-
tions, anemia, preeclampsia, placental abruption, fetal death, preterm birth, and 
low birth weight [55–58].
8.6 Alloimmune dysfunction
• Elevated CD56+ lymphocyte levels
• Increased NK cell levels in the secretory phase of endometrium
• Higher levels in NK cells during the endometrium secretory phase. Strong 
association between maternal type Th2-cell immunity and successful preg-
nancy outcome. Recurrent abortions: associated with immunity type Th1 (lF-γ, 
TNF, lL-12, 58)
8.7 Diminished ovarian reserve
Increased levels of FSH in the early follicular phase of menstrual cycle are sig-
nificant for diminished ovarian reserve. In the least years, another marker antimül-
lerian hormone is better to identify the number of follicular units for recruitment. It 
is recommended that women with RPL visit healthcare services to have appropriate 
counselling to treat endocrinological disorders [59].
8.8 PCOS
Polycystic ovary syndrome (PCOS) is associated with increased frequency 
of RPL and has an uncertain prevalence, because factors associated with PCOS 
such as obesity, insulin resistance, LH rise, and hyperandrogenemia may be the 
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reason and not PCOS as a whole [60–68]. The incidence of abortions in spontane-
ous ovulation is difficult to determine. Diagnostic criteria for this heterogeneous 
disorder have not been present in the past. Hypersecretion of LH and elevate 
androgen levels possibly led to RPL [60–68]. The association of excess androgens 
and RPL is not clear. The hyperinsulinemia in PCOS that is a consequence of insu-
lin resistance involving plasminogen activator inhibitor-1(PAI-1) which inhibits 
plasminogen activation and subsequent fibrinolysis, has potential thromboem-
bolic effect that makes women with PCOS in high risk for recurrent pregnancy 
loss [60–68].
8.9 Why LH rise may result in abortion
• premature oocyte maturation
• hyperandrogenemia may impact on oocytes
• high androgens may affect endometrium
8.10 Role of androgen abortion
• androgens may affect endometrium
• in vitro studies show inhibitory effect of androstenedione
• in endometrial cell growth and activity (glycodelin secretion)
• glycodelin inhibits endometrial immune response to the embryo [60–68]
8.11 Endometrium
• gene hoxa10 is thought to be essential for implantation.
• the expression of this gene is decreased when testosterone is elevated.
8.12 Hyperinsulinemia: abortion
Preimplantation environment is affected by decreasing:
1. expression of glycodelin—which inhibits endometrial immune response to the 
embryo and
2. IGF—binding protein-1, which facilitates adhesion progress at the fetoma-
ternal interface. Plasma plasminogen activator inhibitor-1 concentrations 
are increased in hyperinsulinemia leading to hypofibrinolytic state and 
 thrombophilia [60–68]
8.13 PCO—abortion: thrombophilia
Plasminogen activator inhibitor gene (PAI-1) activity (i.e., hypofibrinolysis) is 
elevated in PCO.
Metformin reduces gene activity from 42.5 to 12.4 U/ml, that is, correct tendency 
for thrombosis which improves uteroplacental flow.
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9. Metformin treatment
PAI-1 activity fell 44% in women with live births.
PAI-1 activity increased 19% in women with abortion.
10. Pregnancy loss and possible beneficial effects of metformin
1. Decreased levels of androgen may improve endometrial function; IR resistance 
is decreased
2. Glycodelin and IGF-1 protein expression is corrected
3. Glycodelin inhibits endometrial immune response to the embryo
4. IGF-1 improves the adhesion process at the fetomaternal interface
5. Hypofibrinolytic activity is reduced by decreased PAI-1 activity (which 
induces hypofibrinolytic activity) [60–68].
11. The prevalence of abortion in PCO is probably elevated
1. Obesity very probably implicated
2. Insulin resistance probably but may INDIRECTLY affect the parameters which 
are influenced by metformin
3. The role of LH needs to be elucidated
4. Endometrial factor probable
5. Oocyte factor probable
6. PAI-1 factor probable
7. Further prospective studies needed to elucidate the significance of these 
factors
Usually, women with PCOS require different treatments due to variety of 
reasons so we can use metformin, diet and infertility drugs. Therapeutic manage-
ment combines normalization of weight and administration of metformin to reduce 
mainly the RPL rate [60–68].
12. Infections
Any infection with high fever can lead to miscarriage rubella virus, cytomega-
lovirus passing the placenta and affecting the fetus, malaria, mycoplasma, and 
trypanosomiasis.
Several studies have confirmed the role of infections as a cause of miscarriage 
especially in the second trimester of pregnancy; however, their role in the first 
trimester miscarriages remains unclear [69–74].
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12.1 Infective factors’ mechanisms of action
Toxic metabolic bio-products, endotoxins, exotoxins, or cytokines may have a 
direct effect on the uterus and the fetoplacental unit chronic endometrial infection 
following after lineal infection (M. hominis, Chlamydia, Ureaplasma urealyticum, 
and HSV) may affect the fetus implantation. Fetal infections are possible to cause 
fetal death or severe malformations incompatible with fetal livability (rubella, par-
vovirus B19, CMV, HSV, and syphilis). Placental infection probably causes placental 
deficiency with consequent fetal death. Amnionitis in the first trimester may have a 
similar effect on chorioamnionitis in the third trimester (causing premature labor). 
Various microorganisms with such effect, as L. monocytogenes, are suspected 
[69–74].
12.2 Correlation between the various supposed mechanisms of automatic 
abortions and specific infectious factors
Mechanisms:
1. Embryotoxicity
2. Placental deficiency
3. Endometritis/endocervicitis
4. Amnionitis
Microorganisms: rubella, parvovirus B19, CMV, HSV, syphilis, Chlamydia, 
Mycoplasma, Ureaplasma, and various Gram-positive or Gram-negative bacteria 
(L. monocytogenes).
None of the above-mentioned infectious agents are usually confirmed to lead to 
RPL. Each high fever infection may lead to pregnancy loss. Viruses such as rubella 
and cytomegalovirus infection (CMV) go through the placenta and affect the 
embryo, as well as lead to malaria, chlamydia, mycoplasma, and trypanosomiasis 
[69–74].
Quite a few studies have confirmed that infections are to blame when it comes to 
miscarriages, especially during the second trimester of pregnancy; however, their 
role in the first trimester miscarriages remains unspecified.
12.3 Recurrent miscarriages of unknown etiology
New techniques in molecular biology and genetics could recognize the impor-
tance of “locality” for mutations. Detection of new mutations in immunological 
and other molecules is involved in the pathophysiology of abortions. It is of great 
importance to immediately start appropriate antibiotic therapy based on a test of 
cure culture, when cervical and vaginal infections are identified and to extend the 
treatment for both parents [75, 76].
12.4 Thrombophilia
Pregnancy is a condition that predisposes to hypercoagulation. The pregnant 
woman is in a state of increased tendency for coagulation (hypercoagulable 
state). The action of the fibrinolytic system decreases during pregnancy, 
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particularly in the placenta, mainly due to an increase in inhibitors of the plas-
minogen activator [77–84].
Pregnancy and coagulation mechanisms include the following:
• Increase of coagulation precursors (procoagulant factors)
• Decrease in levels of physiologically existing anticoagulant factors (naturally 
occurring anticoagulants)
• Reduction of fibrinogenolysis
• “Modified” maternal response to hemostasis (‘disordered’ maternal hemo-
static response) [77–84]
Correlation not quite clear!
Pregnancy is a state of hypercoagulation (hypercoagulable state). This hyper-
coagulable state do not necessarily causes thrombosis and the miscarriage is not 
due to thrombosis.and a lot of patients with miscarriages. This predisposition for 
thrombosis may lead to malfunction in the fetoplacental unit. A disorder in the 
balance between activators and inhibitors of plasminogen can lead to defective pla-
centation [77–84]. The infiltration of trophoblast in arcuate arteries is essential for 
implantation, placentation, and consequently a regular continuation of pregnancy. 
Defective penetration is a common pathological finding in placenta preparations 
by women with excretion and also preeclampsia or intrauterine fetal growth delay 
[77–84].
Placenta abnormalities include excessive implantation and placenta accreta.
Increasing thrombophilic factors and five more frequent thrombophilic poly-
morphisms: a) V Leiden factor; b) MHTHFRC 677T; c) MTHFRA1298C; d) Factor 
VA1299H; and e) factor II G20210A are predisposition to venous thromboembolism 
(VTE). None of the five thrombophilic mutations, alone or in combination, was 
found to significantly increase the risk of miscarriages [77–84].
12.5 Thrombophilic factors
V Leiden: women with RPLs and V Leiden mutation: there is no discrimination 
test for those who will have recurrent miscarriages from those that have a term 
pregnancy.
Treatment: prophylactic administration of heparin without the confirmation of 
RCT is prescribed for known mutations of the factor V Leiden and also for the cases 
that there is indication of placental thrombosis [77–84].
C677T MTHFR polymorphism: previous studies have shown conflicting 
results between the MTHFR C677T genotype and the recurrent miscarriages.
5,10-methylentetrahydrofolate reductase catalyzes the conversion of 5,10-meth-
ylentetrahydrofolic acid to 5-methyltetrahydrofolic acid.
5-methyltetrahydrofolic acid takes part in the methylation of homocysteine in 
methionine.
Substitution of a cytosine molecule by a thymine molecule at position 677 
increases the incidence of homocysteine and thrombophilia.
The reduced activity of MTHFR and hyperhomocysteinemia is clinically mani-
fested when lack of folic acid coexists [77–84].
Treatment: administration of 0.5–2 mg of folic acid leads to homocysteine 
normal levels [77–84].
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12.6 Combination of multiple mild thrombophilic factors
12.6.1 Plasminogen activator inhibitor (PAI)
Increased activity of PAI: genetic factors, metabolic disorders of insulin resis-
tance syndrome, hypertension, smoking, etc.
PAI-1: the major physiological inhibitor of plasminogen activation plays a central 
role in fibrinolysis.
PAI-2: trophoblast and macrophages. Increased PAI activity has been linked to 
recurrent miscarriages.
4G polymorphism of PAI-1 gene is associated with high levels of PAI-1 and 
reduced fibrinolytic activity.
Homozygous for 4G has been complicated with preeclampsia, prematurity, 
IUGR, and placental ablation.
12.7 Combining multiple subtle thrombophilic factors
12.7.1 Factor XII deficiency (Hagemann)
• low molecular weight heparin (LMWH)
• heparin
• LMWH vs. heparin
• one injection per day
• anti-Xa follow-up is not necessary
• decreased risk of osteoporosis 
• reduced risk of thrombocytopenia
• safe for the fetus as it does not pass the placenta
• more likely outcome in obstetric complications [77–84]
12.8 Increase of homocysteine and thrombophilia
As mentioned before, decreased MTHFR activity and hyperhomocysteinemia 
are only obvious as long as there is folic acid deficiency. Substitution with folic acid 
prevents any phenotypic expression of C677T polymorphism.
Prediction for women with polymorphism who are going to have a spontaneous 
abortion [77–84]:
Treatment: the administration of 0.5–2 mg folic acid reduces homocysteine 
levels to normal [77–84].
Homocysteine: homocysteine is an amino acid formed as an intermediate of 
metabolism of methionine. Elevated blood levels of homocysteine (hyperhomo-
cysteinemia) consist an important cardiovascular risk factor, which in recent years 
have significance similar to hypercholesterolemia [85–90].
The detection of women with congenital hyperthyroidism that have much more 
frequent complications in gestation has led to an investigation of the association 
between homocysteine and pregnancy complications associated with placental 
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vascular lesions such as placental abruption, preeclampsia, abortions, fetal death, 
and restriction of intrauterine fetal growth. Hyperhomocysteinemia is also associ-
ated with spinal tube deficits due to folic acid insufficiency. The result that women 
with hyperhomocysteinemia of relative cause show complications much more 
frequently has led to the investigation of obstetric complications with homocys-
teine, which are relevant with vascular placental failure such as placental abrup-
tion, pre-eclampsia, recurrent miscarriages, stillbirth, and intrauterine growth 
 restriction [85–90].
Methionine consist of an important amino-acid that participates in cell growth 
and division by providing methyl groups in the biosynthesis of t-RNA, DNA, and 
proteins. Methionine constitutes a necessary amino acid that plays a crucial role 
in cellular increase and division by providing methyl groups to t-RNA, DNA, and 
protein biosynthesis. Homocysteine is synthesized after a methyl group transposi-
tion from methionine. The 50% could be catalyzed with a sulfureted group trans-
position into cystathionine. The remaining 50% of homocysteine may be reformed 
to methionine by removing a methyl group from two sources: (1) the metabolism of 
tetrahydrofolic acid (THF) and (2) the catabolism of betaine. Three enzymes take 
part in these metabolic pathways: methionine synthetase (MS), cysteine synthetase 
(CBS), and methyl-tetrahydrofolic acid reductase (MTHFR). Vitamin B6 (pyridox-
ine) consists of a coenzyme in the CBS and MTHFR function, while B12 is a coen-
zyme in the MS function. The adequacy of folic acid is necessary for both functions. 
The vascular endothelium may only produce CBS and MTHFR, rendering it more 
sensitive to disturbances in homocysteine metabolism [85–90].
Homocysteine levels >15–16 μmol/l in nonpregnant women and >6–8 μmol/l in 
the third trimester of pregnancy are considered abnormal. In pregnancy, homocys-
teine levels decrease progressively and reach a minimum in the second trimester, 
while increasing slightly in the third trimester. Causes of fluctuations are estrogen, 
blood dilution, and increased metabolism of homocysteine in the liver, as well as 
its removal to the fetus. Mild disturbances in homocysteine metabolism can be 
detected if its levels are measured 6 hours after methionine administration. In 
this case, levels >51 μmol/l are considered pathologically out of pregnancy, but for 
pregnancy, there are no measurements [85–90].
Generally, the increase in basal levels of homocysteine represents deficits in 
remethylation, whereas the increase in homocysteine after methionine loading 
reveals deficiencies related to the transfer of the sulfur group.
Hyperhomocysteinemia may be related to mutations in genes controlling the 
production of CBS and MHTFR and environmental factors such as B6, B12, and 
folic acid deficiency. Drugs that interfere with the metabolism or absorption of 
these vitamins, decreased homocysteine excretion in chronic renal failure, and 
other causes (hypothyroidism, hepatic failure, malignant anemia, and cancer) 
cause hypercholesterolemia [85–90].
It is worth highlighting cases with genetic mutations of the enzymes that cause 
hyperomyeloidemia, because they are common and appear to play a role in the 
course of pregnancy [85–90].
12.9 Laboratory criteria
Antibodies vs. cardiolipins: anti-cardiolipins lgG or lgM, in medium or high 
levels in 2 or more cases, with a time distance of at least 6 weeks between them.
Lupusanticoagulant: in two or more cases with a time distance of at least weeks 
between them.
• Antiphospholipid antibodies
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• Acute infections
• Medicine (chlorpromazine and hydralazine)
• Chronic infections (syphilis and hepatitis C)
• No thrombotic effects
• Antiphospholipid syndrome
• Recurrent abortions
• Endometrial death
• Pre-eclampsia
• IUGR
• B2 glycoprotein 1
• Annexin-V: a protein with strong, anticoagulant action.
• Multiple placental micro-thrombosis [85–90].
13. Pregnancy and hyperhomocysteinemia
The existence of high homocysteine levels in the blood has a harmful effect on the 
placenta and decidua and is associated with the appearance of recurrent abortion and 
placental abruption. Hyperhomocysteinemia has been found to cause more complica-
tions such as pre-eclampsia, stillbirth, and deceleration of intrauterine growth [85–90].
13.1 Hyperhomocysteinemia and spinal tube deficiency
Hyperhomocysteinemia and spinal tube deficiency (NTD) are associated with 
insufficient MS and MFTHR function, leading to homocysteine accumulation. 
Reduced methionine methylation and methyl group (necessary for myelin creation) 
deficiency are responsible for the above complications and not homocysteine effects 
[10]. Low folic acid levels or reduced intake in cases with increased need (heat 
sensitive MTHFR) are responsible for spinal tube deficiencies, but also homocyste-
ine level increase. Hyperhomocysteinemia has also been associated with congenital 
abnormalities on the face and body. Administering 500 mg folic acid for 4 weeks 
prior to conception or even at the first stage of pregnancy has been found to reduce 
homocysteine levels by 22% [90–95].
The gene C677T and MTHFR frequency combined with the dietary habits 
of a population are the reason for variety in NTD appearance in different 
populations. In Holland, homozygous C677T of MTHFR polymorphism carri-
ers is at 10–16% NTD risk compared to 5% of witnesses. A1298C, a second type 
of polymorphism, was discovered with just as high risk NTD levels in case of 
homozygosity [90–95].
13.2 Hyperhomocysteinemia and pre-eclampsia
Several researchers compared patient groups with witnesses, found an increased 
hyperhomocysteinemia frequency, as well as increased C677T of MTHFR mutation 
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frequency in women with pre-eclampsia. So, they were led to the conclusion that it 
may also constitute a genetic factor in pre-eclampsia manifestation [90–95].
In large woman study groups where homocysteine levels were evaluated in the 
second trimester of gestation either prospectively or recursively, it was found that 
the relevant pre-eclampsia risk in women with hyperhomocysteinemia was between 
1.32 and 3.2%, while in primigravida, it reached 9.7% and in those who were obese, 
it reached 6.9%. Certainly, patient choice (with heavy, premature pre-eclampsia) 
has a lot to do with the various levels of pre-eclampsia in incidence of appearance of 
hyperhomocysteinemia in the bibliography. In a prospective study of 1049 pregnant 
women, at their 16th week of gestation, homocysteine levels did not appear to be 
different amongst patients with an uncomplicated course of gestation and those 
with pre-eclampsia. It is undetermined whether homocysteine levels should be 
evaluated in all women with a history of serious pre-eclampsia in a previous preg-
nancy. Repeated studies in women with angiopathy and high homocysteine levels 
have proved that pre-eclampsia was seven times more frequent in their pregnancies 
when compared to those with normal homocysteine levels. Homocysteine does not 
appear to activate the endothelium as there was not found a comparison between 
fibronectin and homocysteine during the episode of pre-eclampsia. A study 
revealed that administration of folic acid and vitamins in women with a history 
of heavy early course pre-eclampsia decreases its frequency and severity in the 
subsequent pregnancy, but because these studies were quite small and not random, 
other greater ones are in progress. At the moment, no specific genotype has been 
associated with more severe or premature types of the disease. Therefore, homozy-
gosity in C677T had an applicable pre-eclampsia risk of 2.6% (95% CI 1.4–5.1) and a 
hyperhomocysteinemia risk of 20.6% (95% CI 3.6–121.6) [90–95].
13.3 Hyperhomocysteinemia and recurrent abortions
High homocysteine levels have proven to be embryo toxic in guinea pigs through 
the vascular decidua and villi network destruction. Steegers-Theunissen and Co. 
found that between 8th and 12th week of pregnancy, there are high methionine 
levels and low homocysteine levels in the extra-embryonic cavity and amniotic 
fluid compared to the mother, suggesting that homocysteine accumulation may 
be toxic. Increased miscarriages in the first trimester are not linked to angiopathy, 
but to methyl group deficiency and defective DNA composition. Wouters and Co. 
were the first to notice the high hyper-homocysteinemia frequency in the 14% of 
cases with recurrent abortion with no prior normal pregnancies and in 33% of 
those with a history of normal pregnancy. Another study in 100 patients with a 
history of consecutive spontaneous abortions found homocysteinaemia in 12% 
of them, C677T of MTHFR mutation in 20%, and decreased folic acid levels in 
15% of patients. Supplementation of high levels (15 mg) of folic acid and vitamin 
B6 (750 mg) to 28 patients with recurrent abortion cases improved homocysteine 
levels and the 17 pregnancies that followed had a successful outcome. In an after-
analysis, homocysteine presence with or without methionine loading showed 
an increased hyper-homocysteinaemia risk by 4.2 and 2.7%, respectively. In 
another study where MTHFR genotypes were sought after in embryonic tissues 
and newborns, all genotype associations were found in embryonic tissue, while in 
newborns, there were no combinations of three or more mutant alleles. This reveals 
that embryos with a lot of mutations may be miscarried. As a result, it is proved 
that there is a correlation between homocysteine metabolic disorder and habitual 
abortions, but it is not clear whether administering vitamins before conception 
may prevent them [95–100].
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13.4 Hyperhomocysteinemia and placental abruption
Placental biopsy in cases with abruption shows vasculopathy compatible 
with stenosis, necrosis, thrombosis, and atherosclerosis in the spinal arteries. 
Homocysteine in blood vessels acts by removing the methyl groups necessary 
for the DNA composition of multiplying cells. In many studies, hyperhomocys-
teinemia has been linked to placental abruption. In an after-analysis, folic acid 
deficiency was found to increase placental abruption frequency by 25.9% (95% 
CI-736.3) and hyperhomocysteinemia by 5.3% (95% CI 1.8–15.9). The presence 
of C677T of MTHFR polymorphism increases placental angiopathy risk by 2.45% 
(95% CI 1.00–6.02). In placental angiopathy cases, endothelium proteins are 
released in the blood, such as the von Willebrand factor (vWF), the activator of 
plasma tissue tPA (tissue plasma activator), the inhibitor of this activator PAI-1 
(plasma activator inhibitor-1), fibronectin, and thrombomodulin that act as 
malfunction indicators. Women with hyperhomocysteinemia appeared to have a 
disproportionate tPA/PAI-1 ratio and a high vWF, while women with a placental 
abruption history had a high vWF and thrombomodulin. Thrombomodulin levels 
were in proportion with homocysteine levels. Administering antioxidant vitamins 
(folic acid, pyridoxine, and hydroxocobalamin) reduced the tPA/PAI-1 ratio but 
did not affect vWF, while the sole administration of folic acid reduced vWF levels. 
Combining hyperhomocysteinemia with thrombophilia, increases placental abrup-
tion risk by 3.4 [95–100].
Finally, angiopathy resulting from hyperhomocysteinemia may be at least 
theoretically involved in placental abruption, therefore it may be useful for cases 
with abruption in the future to be checked for thrombophilia and hyperhomocyste-
inemia and receive antioxidant vitamin treatment [95–100].
13.5 Other cases of hyperhomocysteinemia effects during pregnancy
Hyperhomocysteinemia may be associated with increased endometrial death 
by different mechanisms such as congenital disorders and pre-eclampsia, but its 
significance as an independent factor is in question. In a small group of patients, 
it was found to coexist with 11% frequency, while in a different group it was no 
more apparent than the rest of the population. The findings for its role in slowing 
intrauterine growth are contradictory. In another group of patients, hyperhomo-
cysteinemia levels were as high as 38% and in a different group that was checked 
after methionine loading in women with a history of slowing intrauterine growth, 
hyperhomocysteinemia levels reached 19.2%. On the contrary, in a recursive review 
of the course of pregnancy in women who were CBS mutation carriers, newborns 
did not appear to have lower birth weight [95–100].
14. Hyperhomocysteinemia treatment
Treatment with vitamin B6, B12, and folic acid on its own or combined with 
other vitamins has been evaluated on small groups of patients with coronary artery 
disease and obstetrical complications and has been found to induce homocysteine 
levels and incidents by 30–50% in these groups. In other studies, vitamin C and E 
were given as antioxidant factors. The significance of adding aspirin or heparin in 
these groups still remains questionable, even though we can conclude that normal-
izing homocysteine levels should be enough, in order to achieve the therapeutic 
response. From the above-mentioned factors, we can estimate that even if there 
is no unanimity, it is within reason to check homocysteine levels in cases with a 
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history of NTD, pre-eclampsia, recurrent abortions, and perhaps in cases with 
placental abruption and endometrial death. It is valuable to look further into the 
results from administering vitamins in these cases [95–100].
15. Further investigations
We and other researchers have been searching for such predictive blood 
biomarkers of miscarriage. Macrophage inhibitory cytokine 1 (MIC-1), which is 
During the first trimester of gestation macrophage inhibitory cytokine 1 (MIC-1), 
which is presented in the syncytiotrophoblast and deciduas increases in serum and 
it is proposed to play an immunomodulatory role in the progression of the preg-
nancy. Pregnancy is considered as an ideal condition to study the regulation mecha-
nisms of vascular growth under physiologic circumstances. Fetal vasculogenesis, 
angiogenesis, and vascular adaptation of the uterine circulation are one of a kind 
[101–104]. There is strong evidence bracing a close relationship between embryonic 
development and the state of vascularization of the chorionic villi. Normal chori-
onic villous vascularization is crucial for the normal development of pregnancy. 
However, it is not well known whether abnormal changes in utero-placental vascu-
lar development predispose to abortions [101–104]. The development of a normal 
functioning placental vascular network requires an important degree of coordina-
tion between various angiogenic and angiostatic factors and is exquisitely depen-
dent on signals exchanged between these factors. Abnormalities in the development 
of placental vasculature may generate a number of gestational pathologies including 
miscarriages, intrauterine fetal death (IUFD), intrauterine growth restriction 
(IUGR), placental abruption, and preeclampsia. The importance of angiogenesis 
and angiogenetic factors in pregnancy is well known, and it has been proved that 
chemokines and their receptors are implicated in pregnancy and abortion, while 
cytokines and chemokines have a crucial part in controlling immune cells; these 
molecules are synthesized at the maternal-fetal interface where they have been 
implicated to play critical roles in the establishment and maintenance of pregnancy. 
In addition, they take part in other biological processes, such as cellular lymphoid 
organogenesis, and expression of adhesion molecules. The role of chemokines in 
angiogenesis during pregnancy has been experimentally demonstrated in cultures 
of leukocyte-free first trimester gestational decidual cells and in spontaneous 
miscarriage in mice, but the angiogenetic and angiostatic role of chemokines in the 
placental growth and decidua has not been well demonstrated [101–104]. These 
preliminary results propose a disturbance of the chemokine-associated angioge-
netic network with a significant number of spontaneous abortions during the 1st 
trimester of gestation.
16. Conclusion
Miscarriage is the most usual complication of pregnancy. There are currently 
no definite predictive tests and treatments that can prevent spontaneous miscar-
riage. While 50% of miscarriages are associated with fetal chromosomal faults, 
most of the remaining cases are likely to be euploid fetuses that have failed due 
to implantation problems. Numerous investigators have previously figured that 
developing an accurate predictive test for miscarriage may open the window for 
identifying euploid pregnancies that are still viable but intended to miscarry. It 
follows therefore that possibly, emerging therapeutics could be targeted at such 
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(i.e., rescuing some from miscarriage). The treatment of miscarriages and espe-
cially RPL has a wide variety and should be targeted at the reason. It could be 
complicated to recommend general therapeutic management especially if they 
are unproven, invasive, and expensive, because most couples with unexplained 
recurrent miscarriages have a good outcome. Further investigation of the factors 
that regulate the possible transcriptional repression of angiogenic chemokines 
and/or the overexpression of the angiostatic chemokines could cooperate in early 
prediction and prevention of spontaneous abortions. We assume that an accurate 
investigation of chemokine networks possibly taking part in the angiogenetic 
mechanisms of pregnancy would assist in the design of more accurate and pos-
sibly individualized angiogenesis-associated strategies for improving the early 
prediction and prevention of spontaneous abortion.
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